Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Front Immunol. 2022 May 13;13:855311. doi: 10.3389/fimmu.2022.855311. eCollection 2022.
This study aimed at assessing the safety and immunogenicity of SARS-CoV-2 vaccines in patients with thyroid cancer.
This observational study included thyroid cancer patients between April 1, 2021, and November 31, 2021, in the Second Affiliated Hospital of Chongqing Medical University. All participants received at least one dose of the SARS-CoV-2 vaccine. SARS-CoV-2 IgG was tested, and the interval time between the last dose and humoral response test ranged from <1 to 8 months. The complications after SARS-CoV-2 vaccines were recorded.
A total of 115 participants at least received one dose of SARS-CoV-2 vaccines with a 67.0% IgG-positive rate. Among them, 98 cases had completed vaccination, and the positivity of SARS-CoV-2 IgG antibodies was 96% (24/25) with three doses of ZF2001. SARS-CoV-2 IgG antibodies' positivity was 63.0% (46/73) of two doses of CoronaVac or BBIBP-CorV vaccine. Additionally, after 4 months of the last-dose vaccination, the IgG-positive rate (31.6%, 6/19) significantly decreased in thyroid cancer patients. The IgG-positive rate (81.0%, 64/79) was satisfactory within 3 months of the last-dose vaccination. Ten (10.2%) patients had side effects after SARS-CoV-2 vaccination. Among them, two (2.0%) patients had a fever, five (5.1%) patients had injection site pain, one (1.0%) patient felt dizzy, and one patient felt dizzy and had injection site pain at the same time.
SARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients. The regression time of SARS-CoV-2 IgG is significantly shorter in thyroid cancer patients than in healthy adults. Therefore, a booster vaccination dose may be earlier than the systematic strategy for thyroid cancer patients.
本研究旨在评估 SARS-CoV-2 疫苗在甲状腺癌患者中的安全性和免疫原性。
本观察性研究纳入了 2021 年 4 月 1 日至 2021 年 11 月 31 日期间在重庆医科大学第二附属医院的甲状腺癌患者。所有参与者均至少接受了一剂 SARS-CoV-2 疫苗。检测了 SARS-CoV-2 IgG，并记录了末次疫苗接种与体液反应检测之间的间隔时间，范围为 <1 至 8 个月。记录了 SARS-CoV-2 疫苗接种后的并发症。
共有 115 名患者至少接受了一剂 SARS-CoV-2 疫苗，IgG 阳性率为 67.0%。其中 98 例完成了全程接种，ZF2001 三剂组 SARS-CoV-2 IgG 抗体阳性率为 96%（24/25），科兴中维或 BBIBP-CorV 两剂组阳性率为 63.0%（46/73）。此外，末次接种后 4 个月，甲状腺癌患者 SARS-CoV-2 IgG 阳性率（31.6%，6/19）明显下降。末次接种后 3 个月内 IgG 阳性率（81.0%，64/79）满意。10 例（10.2%）患者 SARS-CoV-2 疫苗接种后出现不良反应。其中 2 例（2.0%）患者发热，5 例（5.1%）患者注射部位疼痛，1 例（1.0%）患者头晕，1 例患者同时头晕和注射部位疼痛。
SARS-CoV-2 疫苗（科兴中维、BBIBP-CorV 和 ZF2001）在甲状腺癌患者中是安全的。甲状腺癌患者 SARS-CoV-2 IgG 的消退时间明显短于健康成年人。因此，甲状腺癌患者加强接种剂量可能早于系统策略。
